The NIDDK Disorders of Gastrointestinal Interoception Consortium Clinical Centers (DGIC)
Contract Overview
Solicitation details, issuing organization, response deadlines, documents, and interested companies for this government contract opportunity.
AI Contract Overview
The National Institute of Diabetes and Digestive Diseases and Nutrition (NIDDK) is expanding its research efforts through a new initiative that builds on the success of the Gastroparesis Consortium (GpCRC). This previous collaboration developed a valuable Gastroparesis Registry containing extensive patient data, including the first U.S. registry for children and adolescents with gastroparesis. Insights from these studies revealed that gastroparesis poses a more complex clinical burden than previously understood, affecting multiple systems beyond the stomach, though the precise mechanisms remain unclear. Expanding the focus, the new consortium aims to explore broader gastrointestinal (GI) disorders linked to impaired interoception — the nervous system's ability to interpret internal bodily signals — which are often implicated in symptoms such as nausea, vomiting, and altered bowel habits. The new entity, called the Disorders of Gastrointestinal Interoception Consortium (DGIC), will incorporate up to six Clinical Research Centers and a Scientific Data Research Center, fostering a multidisciplinary approach to unravel the biological mechanisms that connect GI function to observable symptoms. This work seeks to identify biomarkers for diagnosis and treatment response while employing cutting-edge technologies to discover novel therapeutic targets for future clinical trials. The initiative emphasizes both adult and pediatric GI conditions, advancing the understanding and potential treatment strategies for a range of disorders characterized by dysfunctional interoceptive signaling. Key contacts and further details are available through the NIH and the associated grants portal.
General Info
Agency
NAICS
Place of Performance
Not specifiedSet-Aside
Documents
(0)AI Contract Breakdown
Uniform Contract FormatNo contract breakdown available.
Cannot generate Contract Breakdown because no documents were found from this contract's source.
Timeline
Organization & Contact Information
Full Description
The National Institute of Diabetes and Digestive Diseases and Nutrition (NIDDK) seeks to advance its mission by continuing the work of the NIDDK Gastroparesis Consortium (GpCRC) but also to expand its scope. The collaborative efforts of the GpCRC provided a large database, the Gastroparesis Registry, which is located in the NIDDK central repository and contains information on patients with symptoms of either delayed or normal gastric emptying. It also houses the first U.S. registry of children and adolescents with gastroparesis. The GpCRC provided clarity and insight that set the stage for transforming our understanding of gastroparesis and laid out a road map for approaching other disorders of gastrointestinal (GI) motility. The findings from clinical studies and trials clearly demonstrated that the clinical burden of gastroparesis is significantly greater than previously realized and involves much more than the stomach. Importantly, the underlying mechanisms remain unclear.
Interoception is the ability of the nervous system to sense, interpret and coordinate signals from various bodily systems including the gastrointestinal tract. Many functional GI disorders are associated with a spectrum of overlapping symptoms including nausea, vomiting, and altered bowel habits all of which involve altered interoceptive signaling. This initiative would broaden the scope beyond gastroparesis to include other adult and pediatric GI conditions associated with impaired interoceptive processing to form a Disorders of Gastrointestinal Interoception Consortium (DGIC). The consortium may include up to 6 Clinical Research Centers and a Scientific Data Research Center (SDRC, described in a companion notice). There would be an emphasis on multidisciplinary approaches that would reveal the underlying mechanisms that connect GI function (e.g motility) more directly to symptoms, identify disease or response biomarkers that assess treatment efficacy, and leverage state-of-the-art technologies to identify novel therapeutic targets that could be assessed in future clinical trials.